These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352 [TBL] [Abstract][Full Text] [Related]
3. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820 [TBL] [Abstract][Full Text] [Related]
4. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498 [TBL] [Abstract][Full Text] [Related]
5. Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype. Hu G; Li F; Ouyang K; Xie F; Tang X; Wang K; Han S; Jiang Z; Zhu M; Wen D; Qin X; Zhang L Int J Oncol; 2012 Mar; 40(3):798-806. PubMed ID: 22076649 [TBL] [Abstract][Full Text] [Related]
6. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Shimamura T; Royal RE; Kioi M; Nakajima A; Husain SR; Puri RK Cancer Res; 2007 Oct; 67(20):9903-12. PubMed ID: 17942922 [TBL] [Abstract][Full Text] [Related]
7. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study. Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161 [TBL] [Abstract][Full Text] [Related]
8. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568 [TBL] [Abstract][Full Text] [Related]
9. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152 [TBL] [Abstract][Full Text] [Related]
10. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Garrido-Laguna I; Uson M; Rajeshkumar NV; Tan AC; de Oliveira E; Karikari C; Villaroel MC; Salomon A; Taylor G; Sharma R; Hruban RH; Maitra A; Laheru D; Rubio-Viqueira B; Jimeno A; Hidalgo M Clin Cancer Res; 2011 Sep; 17(17):5793-800. PubMed ID: 21742805 [TBL] [Abstract][Full Text] [Related]
11. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. Hingorani SR; Zheng L; Bullock AJ; Seery TE; Harris WP; Sigal DS; Braiteh F; Ritch PS; Zalupski MM; Bahary N; Oberstein PE; Wang-Gillam A; Wu W; Chondros D; Jiang P; Khelifa S; Pu J; Aldrich C; Hendifar AE J Clin Oncol; 2018 Feb; 36(4):359-366. PubMed ID: 29232172 [TBL] [Abstract][Full Text] [Related]
12. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814 [TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer. Wang K; Baldwin GS; Nikfarjam M; He H Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G632-G640. PubMed ID: 30844294 [TBL] [Abstract][Full Text] [Related]
14. Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine. Fujisawa T; Nakashima H; Nakajima A; Joshi BH; Puri RK Int J Cancer; 2011 Mar; 128(5):1221-31. PubMed ID: 20473925 [TBL] [Abstract][Full Text] [Related]
15. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells. Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329 [TBL] [Abstract][Full Text] [Related]
16. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Heinemann V; Reni M; Ychou M; Richel DJ; Macarulla T; Ducreux M Cancer Treat Rev; 2014 Feb; 40(1):118-28. PubMed ID: 23849556 [TBL] [Abstract][Full Text] [Related]